GlobeNewswire

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
12/11/2025
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients — KRRO-110 did not reach projected levels of functional protein following a [...]
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
12/11/2025
NurExone Honored at Berlin and Stockholm Conferences for Breakthrough Contributions to Global Life Sciences and Health Innovation TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV [...]
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- [...]
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
12/11/2025
Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET [...]
Ascendis Pharma Reports Third Quarter 2025 Financial Results
12/11/2025
– Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ® – Q3 2025 operating profit of €11.0 million – TransCon ® CNP (navepegritide) under FDA Priority Review for the treatment of children [...]
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
12/11/2025
● Q3 Revenue of $8.8 million ● Q3 Cash Collections of $10.0 million ● Q3 Thyroid test volume up 12% year-over-year to record levels ● Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ, [...]
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
12/11/2025
Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform Realigned pipeline [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum